TUMOR INDUCED ANTIGEN SPECIFIC T CELL TOLERANCE

描述：诱导一种已建立起的 通过“治疗性疫苗接种”造成的肿瘤负担目前是有限的。一 对此的解释是，通常防止不适当的机制 对正常组织所表达的“自身”抗原的攻击可能会使 对肿瘤表达的抗原作出反应的能力。的一个关键问题 肿瘤免疫学是指抗原是否通过递增的方式提呈 肿瘤细胞群导致T细胞耐受，如果是的话，如果是这样的话 状态是可逆的。利用TCR转基因小鼠建立模型 一例B细胞淋巴瘤表达肿瘤抗原，研究人员已获得 支持肿瘤诱导抗原特异性存在的证据 随着肿瘤进展而发展的耐受性。总的目标是 这个项目是为了进一步描述这种状态，重点是 它的诱导机制，它发生的环境，以及一个 在主动免疫治疗的背景下探索其可逆性。

DESCRIPTION: The ability to induce the regression of a well established tumor burden via "therapeutic vaccination" is currently limited. One explanation for this is that mechanisms that normally prevent inappropriate attack against "self" antigens expressed by normal tissues may blunt the ability to respond to antigens expressed by tumors. A critical question in tumor immunology is whether antigen presented by progressively expanding tumor cell populations results in T cell tolerance, and, if so, if this state is reversible. Utilizing TCR transgenic mice specific for a model tumor antigen expressed on a B cell lymphoma, the investigator has obtained evidence supporting the existence of tumor-induced antigen specific tolerance that develops with tumor progression. The overall objective of this project is to further characterize this state, focusing on the mechanism of its induction, the settings in which it occurs, and an exploration of its reversibility in the context of active immunotherapy.